Semaglutide in NASH-related cirrhosis: still a long way to go?

Lancet Gastroenterol Hepatol. 2023 Aug;8(8):694. doi: 10.1016/S2468-1253(23)00109-7.

Authors

Anshul Bhateja¹, Rajesh Sharma¹, Ashish Chauhan²

Affiliations

¹ Department of Gastroenterology and Hepatology, Indira Gandhi Medical College, Shimla 171001, India.
² Department of Gastroenterology and Hepatology, Indira Gandhi Medical College, Shimla 171001, India. Electronic address: marquez.dvl@gmail.com.

PMID: 37453428
DOI: 10.1016/S2468-1253(23)00109-7

No abstract available

Publication types

Letter

MeSH terms

Glucagon-Like Peptides / therapeutic use
Humans
Liver Cirrhosis / complications
Liver Cirrhosis / drug therapy
Non-alcoholic Fatty Liver Disease* / complications
Non-alcoholic Fatty Liver Disease* / drug therapy

Substances

semaglutide
Glucagon-Like Peptides